DDrare: Database of Drug Development for Rare Diseases

84. サルコイドーシス
［臨床試験数：143，薬物数：221（DrugBank：79），標的遺伝子数：82，標的パスウェイ数：165］

Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 1% lignocaine; 13NH3 PET/CT scan; 18F-FDG; 18F-FSPG; 18F-fluorodeoxyglucose; 18FDG PET/CT scan; 2% lignocaine; 68Ga-DOTANOC; 68Ga-DOTATATE; 68Ga-DOTATATE PET/CT; 99m technetium infliximab; 99mTc-Infliximab; ABPC; ACT-293987 / JNJ-67896049; ACTHAR Gel (adrenocorticotropic hormone); ACTHAR Gel 40 units twice weekly; ACTHAR Gel 80 units twice weekly.; ACZ885; AMPC; ARA 290; ATYR1923; ATYR1923 1.0 mg/kg; ATYR1923 3.0 mg/kg; ATYR1923 5.0 mg/kg; Abatacept; Acthar; Acthar Gel; Acthar gel; Adalimumab; Adrenocorticotropic hormone; All subjects will receive maraviroc 300mg orally twice a day for 6 weeks; Allogeneic stem cell transplantation; Ambrisentan; Anakinra; Analysis of gamma globulin; Antibiotic Regimen; Antituberculous therapy along with steroids; Armodafinil; Atorvastatin; Autologous hematopoietic stem cell transplantation; Azithromycin; Azithromycin 250Mg Capsule; Azithromycin monohydrate; BAL; Bardoxolone; Bardoxolone methyl; Blood sample; Bosentan; Bosentan monohydrate; C11-methionine; CC; CC-100004; CC-220; CC-220 0.3 mg Daily; CC-220 0.6mg Daily; CMK389; CNTO 148; CNTO1275; CNTO148; Calcium; Calcium Citrate with Vitamin D2; Calcium citrate; Canakinumab; Ciclesonide; Clarithromycin; Corticosteroid; Corticotropin; Cu-64 DOTATATE; Cyclophosphamide; Cysteine; D-methylphenidate; DELTACORTENE*10CPR 25MG; DEXAMETHASONE; DOTANOC; Dapsone; Device: Blood pressure; Device: Flexible bronchoscopy in moderate sedation; Device: Nested PCR for formalin-fixed tissues; Device: Nested PCR for fresh tissues; Device: Oxygen saturation; Device: Propofol dosage; Device: Real-time PCR for fresh tissues; Device: Recovery time after bronchoscopy; Dexamethasone; Dexamethasone 0,5mg; Diagnostic Test: 18F-FDG-PET/MRI; Diagnostic Test: 18F-GE180-PET/MRI; Diagnostic Test: 68Ga-DOTA-TOC PET/CT; Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion Imaging; Diagnostic Test: Laboratory testing; Diagnostic Test: Spirometry; Diagnostic Test: simultaneous combined 18F-FDG PET and cardiac MRI imaging; Dotatate; Doxycycline; Ergocalciferol; Ethambutol; FDG; FLUORINE (18F) FLUDEOXYGLUCOSE; Fermented oyster extract; Fludeoxyglucose; Fluorodeoxyglucose; Folic acid; Formalin; Ga-68-DOTA-NOC; Gallium-68 DOTATATE; Gallium-68-DOTA-N-Octreotide; Genetic: RNA Sequencing; Glucocorticoid (prednisone or prednisolone); Gold; Golimumab; Golimumab Liquid in prefilled syringe; H.P. Acthar Gel; Habitrol; Heparin; Human anti TNF-alpha monoclonal antibody; Human anti-IL 12/23 monoclonal antibody; Humira; Hydroxychloroquine; Hydroxychloroquine + Prednisone; ILARIS; IMod.Fc, H-Fcv3-N4; Ilaris; Iloprost; Indium; Indium-111 Pentreotide; Infliximab; Influenza Vaccine; Inhaled Treprostinil; L-METHIONINE ([11C]METHYL); L-methionine; Levaquin; Levofloxacin; Lignocaine; Low dose prednisolone; METHOTREXATE; MTX; Maraviroc; Medium dose prednisolone; Methionine; Methotrexate; Methylphenidate; Methylphenidate (overencapsulated); Methylphenidate 10mg tablets; Methylprednisolone; Methylprednisolone bolus IV 15 mg/kg/d for 3 days.; Minomycin; Mycophenolate; N-acetyl-cysteine; Nelutri™; Nicotine; Nicotine patch; None; OCTREOTIDE; ORENCIA; Octreotide; Octreotide LAR / Sandostatin LAR (LAR=long acting release); Orencia; Other: 18F-FDG; Other: 18F-Fluorodeoxyglucose (18F-FDG) PET/CT; Other: Normal Saline for injection; Oxygen; Oyster; PD 0360324; PDA001 (cenplacel-L); PLAQUENIL*25CPR RIV 200MG; PREDNISONE; Pentoxifylline; Pirfenidone; Prednisolone; Prednison; Prednisone; Procedure: Bronchoalveolar lavage (BAL); Procedure: Bronchoscopy with bronchoalveolar lavage; Procedure: EBB + TBLB + BAL; Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB); Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA); Procedure: EUS-FNA/EBUS-TBNA + BAL; Procedure: Endobronchial forceps biopsy; Procedure: Skin biopsy; Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes; Procedure: venipunctures; Propofol; Quercetin; Radiation: Rubidium PET; Rapamune; Remicade; Repository Corticotropin Injection; Repository Corticotropin Injection -Treatment Extension; Rifampin; Rifampin and azithromycin.; Riociguat; Rituximab; Roflumilast; Rubidium; SELEXIPAG; SIROLIMUS; Sandostatin LAR; Sarilumab; Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1; Schisandra chinensis extract; Seasonal influenza vaccine available for the 2012-2013 vaccine campaign; Selexipag; Sirolimus; Sirolimus Ointment; THALIDOMIDE; Tadalafil; Thalidomide; Tofacitinib; Tofacitinib 5 mg twice daily; Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial; Tofacitinib 5mg [Xeljanz] 1 year open-label extension; Tracleer; Tranilast; Treprostinil; Uptravi; Ursodeoxycholic Acid; Ursodeoxycholic acid; Ustekinumab; Ustekinumab liquid in prefilled syringe; Vitamin D2; Water

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-004148-31-NL (EUCTR)	26/02/2020	15/11/2019	The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial	The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial - PREDMETH trial	pulmonary sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Methotrexate Product Name: methotrexate INN or Proposed INN: methotrexate Other descriptive name: METHOTREXATE Trade Name: Prednison Product Name: Prednison INN or Proposed INN: prednisone Other descriptive name: PREDNISONE	Erasmus Medisch Centrum Dept. of Pulmonology	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	132	Phase 4	Netherlands
2	NCT03593759 (ClinicalTrials.gov)	January 15, 2019	27/6/2018	Cardiac Sarcoidosis Randomized Trial	Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial	Cardiac Sarcoidosis;Sarcoidosis	Drug: Prednisone;Drug: Methotrexate	Ottawa Heart Institute Research Corporation	Canadian Institutes of Health Research (CIHR)	Recruiting	18 Years	N/A	All	194	Phase 3	United States;Canada;United Kingdom
3	NCT03324503 (ClinicalTrials.gov)	December 8, 2017	12/10/2017	A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis	A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis	Sarcoidosis, Pulmonary	Drug: Glucocorticoid (prednisone or prednisolone)	Celgene	NULL	Completed	18 Years	65 Years	All	8	N/A	United States;Netherlands;United Kingdom
4	NCT01210677 (ClinicalTrials.gov)	April 2014	27/9/2010	Cardiac Sarcoidosis Response To Steroids Trial	CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial	Cardiac Sarcoidosis;Sarcoidosis	Drug: Prednisone	Ottawa Heart Institute Research Corporation	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 4	Canada
5	NCT02200146 (ClinicalTrials.gov)	March 2009	10/7/2014	Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).	Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial.	Pulmonary Sarcoidosis	Drug: Prednisone;Drug: Hydroxychloroquine + Prednisone	University of Milano Bicocca	Agenzia Italiana del Farmaco	Completed	18 Years	70 Years	Both	94	Phase 3	Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2008-001340-39-IT (EUCTR)	30/06/2008	13/06/2008	Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS	Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS	Pulmonary Sarcoidosis	Trade Name: PLAQUENIL25CPR RIV 200MG INN or Proposed INN: Hydroxychloroquine Trade Name: DELTACORTENE10CPR 25MG INN or Proposed INN: Prednisone	UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
7	NCT00000596 (ClinicalTrials.gov)	June 1978	27/10/1999	Diffuse Fibrotic Lung Disease		Lung Diseases;Pulmonary Fibrosis;Sarcoidosis	Drug: prednisone;Drug: cyclophosphamide;Drug: dapsone	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	18 Years	N/A	Both		Phase 2	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2019-004148-31-NL
(EUCTR)

26/02/2020

15/11/2019

The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial

The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial - PREDMETH trial

pulmonary sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Trade Name: Methotrexate
Product Name: methotrexate
INN or Proposed INN: methotrexate
Other descriptive name: METHOTREXATE
Trade Name: Prednison
Product Name: Prednison
INN or Proposed INN: prednisone
Other descriptive name: PREDNISONE

Erasmus Medisch Centrum Dept. of Pulmonology

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

132

Phase 4

Netherlands

NCT03593759
(ClinicalTrials.gov)

January 15, 2019

27/6/2018

Cardiac Sarcoidosis Randomized Trial

Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial

Cardiac Sarcoidosis;Sarcoidosis

Drug: Prednisone;Drug: Methotrexate

Ottawa Heart Institute Research Corporation

Canadian Institutes of Health Research (CIHR)

Recruiting

18 Years

N/A

All

194

Phase 3

United States;Canada;United Kingdom

NCT03324503
(ClinicalTrials.gov)

December 8, 2017

12/10/2017

A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis

Sarcoidosis, Pulmonary

Drug: Glucocorticoid (prednisone or prednisolone)

Celgene

NULL

Completed

18 Years

65 Years

All

N/A

United States;Netherlands;United Kingdom

NCT01210677
(ClinicalTrials.gov)

April 2014

27/9/2010

Cardiac Sarcoidosis Response To Steroids Trial

CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial

Cardiac Sarcoidosis;Sarcoidosis

Drug: Prednisone

Ottawa Heart Institute Research Corporation

NULL

Withdrawn

18 Years

N/A

Both

Phase 4

Canada

NCT02200146
(ClinicalTrials.gov)

March 2009

10/7/2014

Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).

Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial.

Pulmonary Sarcoidosis

Drug: Prednisone;Drug: Hydroxychloroquine + Prednisone

University of Milano Bicocca

Agenzia Italiana del Farmaco

Completed

18 Years

70 Years

Both

Phase 3

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2008-001340-39-IT
(EUCTR)

30/06/2008

13/06/2008

Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS

Pulmonary Sarcoidosis

Trade Name: PLAQUENIL*25CPR RIV 200MG
INN or Proposed INN: Hydroxychloroquine
Trade Name: DELTACORTENE*10CPR 25MG
INN or Proposed INN: Prednisone

UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Italy

NCT00000596
(ClinicalTrials.gov)

June 1978

27/10/1999

Diffuse Fibrotic Lung Disease

Lung Diseases;Pulmonary Fibrosis;Sarcoidosis

Drug: prednisone;Drug: cyclophosphamide;Drug: dapsone

National Heart, Lung, and Blood Institute (NHLBI)

NULL

Completed

18 Years

N/A

Both

Phase 2

NULL